Wed 10/22/2014 19:53 ET
DJIA16461.32151.440.92%SOLAR37.061.082.91%GOLD1241.000.850.85%Shanghai2326.5513.030.56%
S&P 5001927.1114.070.73%BANKS22.660.210.92%OIL80.38205.772.56%Nikkei15195.77401.172.64%
NASDAQ4382.8536.380.83%SEMI48.240.571.19%US/EU0.790.430.54%Futures14.001.007.14%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Pinks and BB (AMARANTUS BIOSCI INC - AMBS)    Pinks And BB Top Stock Picks

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add AMBS
  
From: stephen1205 (Rep: 115)Date: 11/27/2012 08:33
Forum: Pinks and BB - Msg #79062 - List AMBS msgs Thread #673478647 (Rec: 0)
Amarantus BioSciences Announces Positive Data for MANF in Delivery
Diffusion Animal Model of Parkinson's Disease

SUNNYVALE, Calif., Nov. 27, 2012 /PRNewswire via COMTEX/ -- Amarantus
BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new
disease-modifying treatments and diagnostics for Parkinson's disease and
Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic
protein MANF, today announced that the Company has successfully completed
experiments demonstrating that MANF has an excellent diffusion profile in the
striatum of rat brains. The striatum is located in the brain, and is partially
responsible for proper movement as part of the basal ganglia network. The
striatum becomes severely compromised in Parkinson's disease due to neurite
retraction from dopaminergic neurons located in the substantia nigra. The data
generated in this study show that when compared to GDNF, a neurotrophic factor
currently in a Phase 2 clinical trial for Parkinson's disease, MANF had a
significantly higher volume of distribution when delivered to the striatum.
These results are part of on-going animal studies to determine the best
localization of delivering MANF to the brain in Parkinson's disease human
clinical studies.

"The data obtained in this study provide strong evidence that volume
distribution from the site of delivery in the brain is unlikely to be an
impediment to MANF's clinical progress," said John W. Commissiong, PhD, Chief
Scientist at Amarantus. "Volume distribution from the site of delivery appears
to have been one of the key shortfalls of previous clinical trials of
neurotrophic factors in Parkinson's disease. These results provide a higher
degree of certainty that MANF is unlikely to fail in the clinic due to
inadequate diffusion volumes."

In studies conducted by Dr. Steven Gill's laboratory at the University of
Bristol, MANF and GDNF were injected directly into the striatum of separate
groups of rats in order to mimic as closely as possible the treatment setting in
humans. Seven days following delivery under best available conditions, MANF's
diffusion volume was ~30% greater than GDNF's.

"The results of this study provide further support to MANF's real-world
potential as a disease-modifying treatment for Parkinson's disease, and
potentially other brain disorders," said Gerald E. Commissiong, President and
CEO of Amarantus. "Diffusion from the site of delivery in the brain has been a
key problem plaguing the development of other neurotrophic factors for
Parkinson's disease for some time. We now have further evidence that MANF
appears to have added biological advantages over other neurotrophic factors in
development, and the Company intends to leverage these results as we continue to
advance our Parkinson's program, as well as explore additional applications for
MANF in orphan disease applications. The Company is currently evaluating various
delivery technologies to clinically deliver MANF to the brain in Parkinson's
disease, and will update the market of its intentions as definitive agreements
emerge."

Large pharmaceutical companies have shown significant interest in neurotrophic
factors for Parkinson's disease for over two decades. In 1993, Amgen acquired
Synergen for $262 million shortly after Synergen successfully completed studies
using GDNF as a protein therapeutic in animal models of Parkinson's disease. In
2007, Genzyme entered into a $150 million partnership with Ceregene to gain
access to ex-U.S. marketing rights Neurturin after Ceregene successfully
completed a Phase 1 clinical study demonstrating safety for Neurturin as a gene
therapy product. Amarantus owns composition of matter and method of use patents
for MANF, including claims for use of MANF as a protein therapy, gene therapy
and as an adjuvant within the context of cell therapy.



Share This Post:


a group effort brings prosperity to all.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser stephen1205: Reward | Watch | IgnoreAMBS: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add AMBS
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.